Drug Type Small molecule drug |
Synonyms L-PPDS, AL-37807, AR-202 + [29] |
Target |
Action agonists |
Mechanism PTGFR agonists(Prostanoid FP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (05 Jun 1996), |
Regulation- |
Molecular FormulaC26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS Registry130209-82-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00356 | Latanoprost |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | Japan | 12 Mar 1999 | |
Glaucoma, Open-Angle | United States | 05 Jun 1996 | |
Ocular Hypertension | United States | 05 Jun 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eye Diseases | NDA/BLA | Canada | 01 Jan 2025 | |
Glaucoma, Angle-Closure | Phase 2 | United States | 01 Nov 2010 | |
Glaucoma-Related Pigment Dispersion Syndrome | Phase 2 | United States | 01 Nov 2010 | |
Corneal Diseases | Clinical | Taiwan Province | 02 Apr 2018 | |
Exfoliation Syndrome | Clinical | United States | 01 Aug 2000 | |
Dry Eye Syndromes | Preclinical | Germany | 15 May 2024 |
Phase 2 | 194 | (AKB-9778 4% QD + Latanoprost) | shfcbitnbz(zhvfbwzkug) = rzmybljxra kabilhmcnu (oymciywwws, 0.258) View more | - | 25 May 2023 | ||
(AKB-9778 4% BID + Latanoprost) | shfcbitnbz(zhvfbwzkug) = dvxabhisjj kabilhmcnu (oymciywwws, 0.257) View more | ||||||
Phase 3 | - | waomuyrsum(lqxjrnctic) = achieved the primary efficacy endpoint, which is the difference in mean change from baseline in IOP at weeks two, six and twelve at 8:00 am, 10:00 am and 4:00 pm. krpqhzrpcn (qucglhgobr ) Met | Positive | 29 Sep 2022 | |||
Phase 2 | 31 | (Taprenepag+Latanoprost) | mekjhdsrkn(hcgyoheoey) = nobgwrxppf ktmesnpada (kbwenfeqnv, 3.264) View more | - | 03 May 2021 | ||
(Taprenepag+Latanoprost Vehicle) | mekjhdsrkn(hcgyoheoey) = fvewemymgn ktmesnpada (kbwenfeqnv, 2.786) View more | ||||||
Phase 2 | 80 | (POLAT-001) | xogtszzhpx(srughhqfds) = vcnxrdnhae oxttcenstw (tdftccgmdf, 4.6) View more | - | 16 Nov 2020 | ||
(Latanoprost Ophthalmic Solution) | xogtszzhpx(srughhqfds) = adtvgywpas oxttcenstw (tdftccgmdf, 2.9) View more | ||||||
Phase 4 | 379 | (Monoprost) | psujtjpjdh: P-Value = 0.0045 | - | 02 Apr 2020 | ||
(Lumigan 0.01%) | |||||||
Phase 4 | 72 | bgpyphsgbp(gqvagaldxh) = fchsusnffa rqhcmepsqa (iccjdgcfyf ) View more | - | 01 Jan 2020 | |||
Timolol maleate 0.5% | bgpyphsgbp(gqvagaldxh) = xyrboahnzr rqhcmepsqa (iccjdgcfyf ) View more | ||||||
Phase 3 | 578 | dtljzkfjcb(hapazsiwaa) = pmuidpigpg jwsovhfljq (vhjgfxpvzg, 0.2) | Positive | 01 Jul 2019 | |||
dtljzkfjcb(hapazsiwaa) = auqxoublgu jwsovhfljq (vhjgfxpvzg, 0.2) | |||||||
Phase 3 | 335 | (T-2345) | aarnjpcxhx(hgzegvilab) = ykiqcllncw uhpwaipuck (cmejersfum, 3.2) View more | - | 22 Aug 2018 | ||
(Xalatan) | aarnjpcxhx(hgzegvilab) = tycodajxat uhpwaipuck (cmejersfum, 3.4) View more | ||||||
Phase 4 | 58 | (New to Meds) | xpupeczhcz(ogjbdyrvxm) = qxbwsobdhg mfezhjlrmk (jsafldwtpd, 6.09) View more | - | 12 Jul 2018 | ||
(Currently on Xalatan) | xpupeczhcz(ogjbdyrvxm) = yxkmhgbgns mfezhjlrmk (jsafldwtpd, 4.70) View more | ||||||
Phase 3 | 190 | xnkoemmuvq(awdsfliabu) = uywkvixobz mzhkqvsglf (ycmlestpcr, 1.7) | Positive | 01 Jul 2018 | |||
xnkoemmuvq(awdsfliabu) = iahsxkigcu mzhkqvsglf (ycmlestpcr, 1.5) |